June 27, 2016

Why revisit your supply chain? The cost of bringing new drugs to market continues to rise. Regulators are demanding more (and more detailed) clinical evidence. Today’s complex molecules – small and large – require an enormous range of technologies that usher in new challenges. Being first to market matters more than ever before. And when you factor in that a growing majority of new molecule development is coming from small and emerging companies, it’s clear that a new method of drug production has to emerge. Biopharma companies of all sizes look to vendors to help manage development, manufacturing, and capacity needs. The question is: are they keeping up?